TheraRadar
Clinical-Stage Companies / Kodiak Sciences

Kodiak Sciences

Pre-Approval PRO BETA
11
Total Trials
10
Phase 3
1
Phase 2
4
Recruiting
171
Score

Pipeline by Phase

Phase 3
10
Phase 2
1
Phase 1
1

Therapeutic Focus

Wet Age-related Macular Degeneration Diabetic Macular Edema Macular Edema Secondary to Inflammation Retinal Vein Occlusion Diabetic Retinopathy

Clinical Trials (11)

NCT06996080 Phase 3 RECRUITING

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

Started: 7/16/2025

NCT06990399 Phase 3 RECRUITING

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Started: 7/30/2025

NCT06556368 Phase 3 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

Started: 8/23/2024

NCT06270836 Phase 3 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Started: 5/1/2024

NCT05066230 Phase 3 TERMINATED

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

Started: 9/7/2021

NCT04603937 Phase 3 TERMINATED

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Started: 9/30/2020

NCT04611152 Phase 3 TERMINATED

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Started: 9/30/2020

NCT04964089 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Started: 6/23/2021

NCT04592419 Phase 3 COMPLETED

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Started: 9/25/2020

NCT04049266 Phase 2 TERMINATED

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Started: 10/8/2019

NCT03790852 Phase 1 TERMINATED

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

Started: 12/26/2018

Drug Candidates

Tarcocimab tedromer Tabirafusp tedromer Aflibercept KSI-101 Tarcocimab KSI-301
Activity Status: Active
Last Trial Started: 7/30/2025
Last Trial Ended: 8/31/2023
Trials (12 months): 2
Completed Trials: 2
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.